Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of “Reduce” from Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus recommendation of “Reduce” by the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $38.2667.

A number of research firms recently issued reports on MRNA. Piper Sandler boosted their target price on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, June 26th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Barclays upped their price objective on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Morgan Stanley increased their price objective on shares of Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their target price on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th.

Insider Transactions at Moderna

In other Moderna news, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the sale, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 125,088 shares of company stock worth $6,193,713 in the last three months. Insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MUFG Securities EMEA plc acquired a new position in Moderna during the second quarter worth $28,000. Allied Private Wealth LLC acquired a new position in shares of Moderna during the second quarter valued at about $30,000. Flagship Harbor Advisors LLC bought a new stake in shares of Moderna during the fourth quarter worth about $31,000. Canton Hathaway LLC bought a new stake in shares of Moderna during the first quarter worth about $31,000. Finally, Cromwell Holdings LLC raised its holdings in shares of Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 10.8%

Shares of Moderna stock traded down $8.29 on Friday, hitting $68.27. 9,157,965 shares of the company’s stock traded hands, compared to its average volume of 9,469,511. The company has a fifty day moving average of $56.20 and a two-hundred day moving average of $49.66. Moderna has a one year low of $22.28 and a one year high of $85.60. The company has a market capitalization of $27.09 billion, a price-to-earnings ratio of -8.38 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the previous year, the firm posted ($2.52) earnings per share. The company’s revenue for the quarter was up 260.2% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna will post -6.56 earnings per share for the current year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna won a European Commission contract to supply its RSV vaccine to six countries, with the deal covering up to 24 million doses. That gives the company a meaningful commercial win and supports expectations for vaccine revenue growth. Moderna wins EU contract for RSV vaccine supply
• Positive Sentiment: RBC Capital raised its price target on Moderna to $45 from $38, signaling improved analyst sentiment ahead of the company’s next earnings update. RBC Capital Raises its Price Target on Moderna (MRNA)
• Positive Sentiment: Options activity surged, with investors buying 77,577 call options, about 45% above normal volume. Heavy call buying often suggests traders are positioning for more upside.
• Neutral Sentiment: Moderna said it will report second-quarter 2026 results on July 31 and hold a conference call to provide a corporate update. Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
• Neutral Sentiment: Media coverage highlighted Moderna’s mRNA flu vaccine progress, including the possibility it could be ready this fall, but distribution and access may still be an issue. Moderna’s mRNA Flu Vaccine Could Be Ready This Fall. Getting It May Be Another Story.
• Negative Sentiment: Shares also fell during a broader biotech selloff, which may have pressured Moderna along with peers despite the company-specific positives. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.